THOLOS-FOUNDATION
The Tholos Foundation, an international non-governmental organization dedicated to advocating for consumers, today launched three white papers exposing the risks of banning flavours in vaping products at an event in Brussels hosted by Parliament Magazine and featuring contributions from Swedish MEP Johan Nissinen. The reports cover the impact of flavour bans in the real world, best practices to educate adult smokers and restrict underage usage, and analyse the public response to the European Commission’s 2023 public consultation.
Surveys commissioned by the Tholos Foundation and conducted by Ipsos in multiple countries have shown that a significant majority of vapers use flavours other than tobacco to help reduce and quit smoking. Notably, 83% of vapers in Germany stated that flavours are crucial in their decision to vape, with similar high percentages reported in Belgium, the Netherlands, and Sweden. The research also showed that, in countries where flavours were banned, many vapers went back to smoking or for black market alternative, and reference numerous scientific studies confirming that flavours are essential for the effectiveness of vaping products in smoking cessation.
With European elections due to take place shortly, it is imperative policymakers take heed of voters’ concerns and reject extensive restrictions on lifesaving smoking alternatives. The new European mandate is expected to drive a new revision of the bloc’s Tobacco Products Directive, and consumers have already overwhelmingly responded to a public consultation overwhelmingly stressing the importance of vapes in helping them quit smoking.
Rather than product bans, the papers examine a menu of policy alternatives to protect public health focussing on improved enforcement of existing laws, restricting flavour descriptors and communications, limiting sales to adult-only stores, and an openness to technological innovations.
Tim Andrews, Director of Consumer Issues and a report author said: “The evidence is clear: flavours in vaping products are critical to helping smokers quit. Banning flavours will create a black market and drive people back to smoking. Our reports offer an evidence-based approach that combines rigorous law enforcement, education, and technological innovations to reduce underage experimentation while preserving the benefits for adult smokers.
“With the European elections approaching, it is crucial for policymakers to understand the importance of harm reduction strategies. Our findings support a balanced approach that protects public health and helps smokers transition to safer alternatives.”
The reports can be downloaded at www.tholosfoundation.org/thr.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530005633/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 17:46:00 CEST | Press release
Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 17:44:00 CEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,
LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 17:00:00 CEST | Press release
~New server connects AI assistants directly to test execution data, streamlining debugging and accelerating development~ LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances aut
The Six Winning Projects of the 12th Edition of the IBSA Foundation Fellowships have been Awarded and the 2025 Call is Now Open27.5.2025 16:58:00 CEST | Press release
The winners of the 2024 IBSA Foundation Fellowships Call come from two US, two Swedish, one Italian and one British universities.This year’s edition set a new record: 259 projects submitted from 45 countries.The awards ceremony was held today in Milan; during the event, the 2025 call for applications was officially opened. Research means investing in the future. This is the guiding principle behind the IBSA Foundation Fellowships programme, which for over a decade has supported talented researchers under 40 from universities and research institutions around the world. The programme awards grants to promote innovative and potentially groundbreaking projects in lesser-explored scientific fields; a constantly growing success, also confirmed by the 2024 edition, which marked a new record, with 259 applications across five scientific areas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522244202/en/ The Award Ceremony of the
Rigaku Completes New Building at Yamanashi Plant27.5.2025 16:00:00 CEST | Press release
Dramatic 2.7-fold increase in floor space to serve global demand Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; hereinafter “Rigaku”) completed an additional manufacturing building (hereinafter “the New Building”) at Yamanashi Plant, Rigaku’s main production facility. The facility was established to serve as the center of Rigaku’s production framework, in anticipation of global business growth and expansion in product demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527974928/en/ Exterior view of the New Building, Yamanashi Plant Doubling of production capacity: a strategic base to support Rigaku’s growth Demand for X-ray analytical solutions has soared in recent years, both in Japan and worldwide. To respond to growing demand, Rigaku implemented this expansion with two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom